World
Amgen's Imdelltra combo cuts risk of death by 58% in lung cancer A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. . A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. .
Luna ReyesEntertainment & Culture EditorPublished Oct 24, 2026 at 7:43 PM EDT · 1 min read
Amgen's Imdelltra combo cuts risk of death by 58% in lung cancer A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. . A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. .
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.